(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 October 2025 (16.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/217230 A1

(51) International Patent Classification:
*A61P 27/02* (2006.01) *C07K 16/18* (2006.01)

(21) International Application Number:
PCT/US2025/023760

(22) International Filing Date:
08 April 2025 (08.04.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

| | | |
|---|---|---|
| 63/631,448 | 08 April 2024 (08.04.2024) | US |
| 63/642,642 | 03 May 2024 (03.05.2024) | US |
| 63/703,110 | 03 October 2024 (03.10.2024) | US |


(71) Applicant: **REGENXBIO INC.** [US/US]; 9804 Medical Center Drive, Rockville, MD 20850 (US).

(72) Inventors: **LILLEY, Brendan N.**; 9804 Medical Center Drive, Rockville, MD 20850 (US). **GUMERSON, Jessica**; 9804 Medical Center Drive, Rockville, MD 20850 (US). **TEPE, April R.**; 9804 Medical Center Drive, Rockville, MD 20850 (US). **YOST, Samantha**; 9804 Medical Center Drive, Rockville, MD 20850 (US). **FIRNBERG, Elad**; 9804 Medical Center Drive, Rockville, MD 20850 (US).

(74) Agent: **BRIVANLOU, Margaret** et al.; Ballard Spahr LLP, 999 Peachtree Street, Suite 1000, Atlanta, GA 20850 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) Title: VECTORIZED ANTI-COMPLEMENT ANTIBODIES AND COMPLEMENT AGENTS AND ADMINISTRATION THEREOF

FIGS. 1A-1C

FIG. 1A




FIG. 1B






FIG. 1C




(57) Abstract: Compositions and methods are described for the delivery of an AAV that comprises a transgene encoding an scFv that binds to C5 to a human subject for treatment of an ocular indication, particularly AMD. The nucleotide sequence encoding the antibody is delivered in a rAAV vector that targets ocular tissue cells for expression of the transgene.

[Continued on next page]

WO 2025/217230 A1

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*